Lawmakers on the U.S. Senate Judiciary Committee urged the Trump administration to conduct a scientific review of a Justice Department-backed bill to classify all illicit chemical knockoffs of the potent painkiller fentanyl in the same legal category as heroin.
Five U.S. states filed lawsuits accusing Purdue Pharma LP of illegally marketing and selling opioids, including OxyContin.
The U.S. Justice Department filed a lawsuit seeking to stop a nonprofit in Philadelphia from opening what could become the nation’s first supervised drug-injection site in an effort aimed at addressing opioid abuse.
A U.S. appeals court revived Swedish pharmaceutical company Orexo AB’s lawsuit accusing a unit of Israel’s Teva Pharmaceutical Industries Ltd. of infringing a patent for the opioid addiction drug Zubsolv.
Emergent BioSolutions will buy privately held Adapt Pharma, beefing up its portfolio with Narcan, the only FDA-approved needle-free emergency opioid overdose treatment.
New York state sued Purdue Pharma LP, accusing the OxyContin maker of widespread fraud and deception in the marketing of opioids, and contributing to a nationwide epidemic.
GW Pharmaceuticals Plc’s epilepsy treatment Epidiolex secured FDA marketing clearance, becoming the first cannabis-based drug to be approved in the United States.
Acetaminophen, ibuprofen and other nonsteroidal anti-inflammatory drugs (NSAIDs) are better than opioids at easing the intensity of chronic pain in the back, knees or hips, a U.S. experiment suggests.
The FDA accepted Indivior’s application for its new once-monthly injectable schizophrenia treatment.
Opioid drug abuse cost the U.S. economy as much as $504 billion in 2015, White House economists said in a report.